EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross‐Sectional Study

Alexandra L Degraeve iD, Laure B Bindels iD, Vincent Haufroid iD, Serge Moudio, Lidvine Boland iD, Kevin-Alexandre Delongie, Joseph P Dewulf iD, Djamila Chaib Eddour, Michel Mourad, Laure Elens iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3077 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, 2024. Written by Alexandra L Degraeve and 9 co-authors. Institution: Department of Integrated PharmacoMetrics, PharmacoGenomics and PharmacoKinetics, Louvain Drug Research Institute, Université Catholique de Louvain, B…. Major MEDLINE topics: Kidney Transplantation, Gastrointestinal Microbiome. Cited 31 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Clinical use of tacrolimus (TAC), an essential immunosuppressant following transplantation, is complexified by its high pharmacokinetic (PK) variability. The gut microbiota gains growing interest but limited investigations have evaluated its contribution to TAC PKs. Here, we explore the associations between the gut microbiota composition and TAC PKs. In this pilot cross‐sectional study ( Clinicaltrial.gov NCT04360031 ), we recruited 93 CYP3A5 non‐expressers stabilized kidney transplant recipients. Gut microbiota composition was characterized by 16S rRNA gene sequencing, TAC PK parameters were computed, and additional demographic and medical covariates were collected. Associations between PK parameters or diabetic status and the gut microbiota composition, as reflected by α‐ and β‐diversity metrics, were evaluated. Patients with higher TAC area under the curve AUC/(dose/kg) had higher bacterial richness, and TAC PK parameters were associated with specific bacterial taxa (e.g., Bilophila ) and amplicon sequence variant (ASV; e.g., ASV 1508 and ASV 1982 ( Veillonella /unclassified Sporomusaceae ); ASV 664 (unclassified Oscillospiraceae )). Building a multiple linear regression model showed that ASV 1508 (co‐abundant with ASV 1982) and ASV 664 explained, respectively, 16.0% and 4.6% of the interindividual variability in TAC AUC/(dose/kg) in CYP3A5 non‐expresser patients, when adjusting for hematocrit and age. Anaerostipes relative abundance was decreased in patients with diabetes. Altogether, this pilot study revealed unprecedented links between the gut microbiota composition and diversity and TAC PKs in stable kidney transplant recipients. It supports the relevance of studying the gut microbiota as an important contributor to TAC PK variability. Elucidating the causal relationship will offer new perspectives to predict TAC inter‐ and intra‐PK variability.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationGastrointestinal MicrobiomeHumansTacrolimusCytochrome P-450 CYP3ACross-Sectional StudiesPilot ProjectsRNA, Ribosomal, 16SImmunosuppressive AgentsGenotype

Substances

TacrolimusCytochrome P-450 CYP3ARNA, Ribosomal, 16SImmunosuppressive Agents

Authors and institutions

  • Department of Integrated PharmacoMetrics, PharmacoGenomics and PharmacoKinetics, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium.
  • Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium.
  • Louvain centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
  • Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Institute of Rare Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Department of Biochemistry, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.

ORCID profiles: Alexandra L Degraeve, Laure B Bindels, Vincent Haufroid, Lidvine Boland, Joseph P Dewulf, Laure Elens

Cite

APA

Degraeve, A. L., Bindels, L. B., Haufroid, V., Moudio, S., Boland, L., Delongie, K. A., Dewulf, J. P., Eddour, D. C., Mourad, M., & Elens, L. (2024). Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross‐Sectional Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3077

Vancouver

Degraeve AL, Bindels LB, Haufroid V, Moudio S, Boland L, Delongie KA, et al. Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross‐Sectional Study. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3077

BibTeX
@article{Degraeve2024,
  author = {Degraeve, Alexandra L and Bindels, Laure B and Haufroid, Vincent and Moudio, Serge and Boland, Lidvine and Delongie, Kevin-Alexandre and Dewulf, Joseph P and Eddour, Djamila Chaib and Mourad, Michel and Elens, Laure},
  title = {Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross‐Sectional Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3077}
}
Start for free →